ACAD Acadia Pharmaceuticals Earnings and EPS analysis

  1. Stocks
  2. Healthcare
  3. NASDAQ: ACAD
  4. Earnings
?
Relative Growth: Rel. Growth: 77
Relative Strength: Rel. Strength: 70
Relative Valuation: Rel. Valuation: 73
Relative Profitability: Rel. Profitability: 93

EPS in 2026 (TTM): $2.25

Last Report Period Date: Jun 30, 2026

Based on the company's latest reports for June 2026, the current EPS (TTM) is $2.25. Acadia Pharmaceuticals's earnings per share in 2025 came in at $2.32, marking an increase from $1.37 in 2024. For the quarterly period ending on Jun 30, 2026, ACAD's earnings per share was $0.18.

ACAD earnings history

Historical annual and quarterly earnings per share (EPS) data for Acadia Pharmaceuticals
EPS (TTM)
$2.25
EPS Growth YoY (Quarterly)
12.5%
EPS (Quarterly)
$0.18
EPS Growth (Quarterly)
800%

Acadia Pharmaceuticals had an yealy EPS of $2.32, marking an increase of 69.3% from $1.37 recorded in 2024. The quarterly EPS for the period ending Jun 30, 2026, was $0.18, marking a 12.5% increase compared to the same quarter last year. ACAD's TTM EPS is $2.25 as of June 2026. Acadia Pharmaceuticals's EPS for 2024 was $1.37, a 470.3% rise from 2023.

ACAD EPS vs price chart

ACAD EPS growth history

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
12.5%
EPS growth YoY
69.3%
EPS growth 3Y avg
N/A
EPS growth 5Y avg
N/A

Acadia Pharmaceuticals has recorded a growth in earnings per share of 12.5% over the past 12 months (YoY, quarterly).

ACAD Earnings Waterfall

Breakdown of revenue, profit and net income for Acadia Pharmaceuticals

ACAD Earnings vs Peers

What are the earnings of ACAD compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
ACAD Acadia Pharmaceuticals Inc 12.61 69.3% N/A N/A
BMY Bristol-Myers Squibb Company 14.21 178.7% 5.3% N/A
JNJ Johnson & Johnson 30.02 90.6% 17.7% 14.8%
PFE Pfizer Inc 35.26 -3.5% -37.4% -3.7%
LLY Lilly(Eli) & Company 40.52 95.6% 49.2% 27.5%
VNDA Vanda Pharmaceuticals Inc N/A -1,033.3% N/A N/A

All data is based on quarterly TTM periods, unless otherwise specified.